18th MEET THE PROFESSOR

Advanced International Breast Cancer Course 2022
(AIBCC 2022)

Padua and online

November 3rd (10:15 – 18:30) | November 4th (09:00 – 16:30)

Presentation

Aims

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.
New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, tio allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
The 18th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

Addressed to

Gynecologists and obstetrics
Medical oncologists
Pathologists

Radiologists
Radiation oncologists
Surgeons

Biologists
Pharmacists
Nurses

Scientific Program

Thursday, November 3rd

10:00

Introduction to the Conference
Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION

Chairpersons: Hesham Ahmed Gaballah Elghazaly, Aleix Prat

10:30	Biological heterogeneity and clinical outcomes in HR+/HER2-negative disease Maria Vittoria Dieci
11:00	PDL1, TMB, TROP2, immune infiltration and genomic classifiers in TNBC Giampaolo Bianchini
11:30	Is HER2-low breast cancer a real entity? Scoring issues and biological heterogeneity Giuseppe Viale
12:00	HER2+ early breast cancer: potential role of genomic classifiers Aleix Prat
12:30	Q&A
13:00	Lunch

SESSION II – CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS
Mastectomy, breast reconstruction and radiation Therapy

Chairpersons: Jaceck Jassem, Philip Poortmans

14:00	When is breast-conserving therapy really not avoidable Oreste Gentilini
14:30	Breast reconstruction: when and how? Vincenzo Vindigni
15:00	Radiation therapy after breast reconstruction Orit Kaidar-Person
15:30	Q&A
	Multidisciplinary Tumor Board 1 – Locoregional treatment Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Fedro Peccatori
16:00	Clinical case 1. Second breast conserving therapy Tania Saibene
16:15	Clinical case 2. Patient with lymph node seen on planning CT-scan: what now? (RT) Silvia Michieletto
16:30	Clinical case 3: BOOP: after or due to radiation therapy Luca Visani
16:45	Concluding comments Eleftherios Mamounas, Fedro Peccatori
17:00	Adjourn
17:45	Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2022
18:00	Lecture of the Awardee
18:30	Cocktail
19:00	Adjourn

The Ceremony and the cocktail will take place in
Palazzo Bo, Via VIII Febbraio 2, Padua

Friday, November 4th

SESSION III – EARLY BREAST CANCER. FINE TUNING FROM DE-ESCALATION TO ESCALATION

Chairpersons: Pierfranco Conte, Miguel Martin.

09:00	Tailoring neoadjuvant/adjuvant treatment for triple negative breast cancer Sibylle Loibl
09:30	Risk adapted treatment of early HR+/HER2- breast cancer: from modulation of endocrine treatment to novel agents Stephen Johnston
10:00	Is there a role for anthracyclines in contemporary treatment of early breast cancer? Valentina Guarneri
10:30	Q&A
11:00	Coffee Break
	Multidisciplinary Tumor Board 2 – Early breast cancer Panelists: Bettina Borisch, Pierfranco Conte, Valentina Guarneri, Jacek Jassem, Stephen Johnston, Sibylle Loibl, Miguel Martin, Fedro Peccatori
11:30	Clinical case 1. Node positive, premenopausal patient: role of genomic classifiers Cristina Falci
11:45	Clinical case 2. HR+HER2+ patient with residual disease after neoadjuvant therapy Federica Miglietta
12:00	Clinical case 3. Adjuvant treatment in rare histologies Grazia Vernaci
12:15	Concluding comments Jaceck Jassem, Miguel Martin
12:30	Lunch

SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS

Chairpersons: Alessandra Gennari, Bettina Borisch.

13:30	HER2+ advanced breast cancer: new treatment algorithms Sandra Swain
14:00	TN advanced breast cancer: biology-driven treatment algorithms Hope Rugo
14:30	HR+ advanced breast cancer: what after CDK4/6? Giuseppe Curigliano
15:00	Q&A
	Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer Panelists: Bettina Borisch, Pierfranco Conte, Giuseppe Curigliano, Hesham Ahmed Gaballah Elghazaly, Hope Rugo, Sandra Swain
15:30	Clinical case 1. Brain metastases Gaia Griguolo
15:45	Clinical case 2. Possibility of discontinuing treatment in very long term responders Carlo Alberto Giorgi
16:00	Clinical case 3. Locoregional treatment for oligometastatic disease or role of NGS in ABC Michele Bottosso
16:15	Concluding comments Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly
16:30	Take home messages and adjourn

In-Class Course

PADUA, November 3rd (10:15 – 18:30) | November 4th (09:00 – 16:30)

ENROLL

Online Course

Online, November 3rd (10:15 – 18:30) | November 4th (09:00 – 16:30)

ENROLL

CME (In-Class & Online)

Based on the applicable regulation, Accademia Nazionale di Medicina (CME provider n. 31) will assign to the activity (ECM 31-355554): 8,4 CME points.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialization and highly specialized activity. Rare disease.

The credit certification for the course is subject to the fulfillment of all following conditions:

Professions/specializations should correspond to those accredited for CME
Attendance no lower than 90% of the meeting duration
Completion of the meeting evaluation online form
Completion of the final test (at least 75% of correct answers). 1 attempt admitted.
Ownership of an Italian Fiscal Code (Codice Fiscale).

The test and the meeting evaluation form must be completed within 3 days from the end of the event.